The necessity to test evidence‐based medical therapy for chronic HF in the setting of acute MI is illustrated by the Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction (PARADISE‐MI) trial, in which sacubitril/valsartan did not reduce the risk of the primary endpoint of cardiovascular death or incident heart failure in high‐risk patients following acute MI.16 This evidence concerns the gene MME and acute myocardial infarction.